Display options
Cite
Yoon N, Cho JG, Kim KH, et al. Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure. Exp Ther Med. 2013;5(4):1009-1016doi: 10.3892/etm.2013.920.
Yoon, N., Cho, J. G., Kim, K. H., Park, K. H., Sim, D. S., Yoon, H. J., Hong, Y. J., Park, H. W., Kim, J. H., Ahn, Y., Jeong, M. H., & Park, J. C. (2013). Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure. Experimental and therapeutic medicine, 5(4), 1009-1016. https://doi.org/10.3892/etm.2013.920
Yoon, Namsik, et al. "Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure." Experimental and therapeutic medicine vol. 5,4 (2013): 1009-1016. doi: https://doi.org/10.3892/etm.2013.920
Yoon N, Cho JG, Kim KH, Park KH, Sim DS, Yoon HJ, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Park JC. Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure. Exp Ther Med. 2013 Apr;5(4):1009-1016. doi: 10.3892/etm.2013.920. Epub 2013 Jan 23. PMID: 23599726; PMCID: PMC3628872.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2013 Apr;5(4):1009-1016. doi: 10.3892/etm.2013.920. Epub 2013 Jan 23.

Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure.

Experimental and therapeutic medicine

Namsik Yoon, Jeong Gwan Cho, Kye Hun Kim, Keun Ho Park, Doo Sun Sim, Hyun Ju Yoon, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Myung Ho Jeong, Jong Chun Park

Affiliations

  1. Department of Cardiovascular Medicine, The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Science, Gwangju 501-757, Republic of Korea.

PMID: 23599726 PMCID: PMC3628872 DOI: 10.3892/etm.2013.920

Abstract

The remodeling of gap junctions may affect their conduction properties and contribute to the maintenance of atrial fibrillation. The significance of the role of angiotensin-II receptor blockers (ARBs) in upstream therapy is not clear. This study was performed to investigate the effects of ARBs on atrial remodeling in a heart failure model. A model of heart failure was established or sham surgery performed in 24 Sprague-Dawley male rats. The rats were divided into sham, heart failure and heart failure-ARB groups. In the ARB group, 30 mg/kg of losartan was administered each day for 4 weeks. Echocardiography was performed at the baseline and 4 weeks following the surgery. An atrial fibrillation induction study and histological and immunohistochemical evaluation were performed 4 weeks after surgery. The increase in the left atrial diameter of the heart failure-ARB group was smaller than that of the heart failure group (P=0.028). The atrial fibrillation inducibility and duration of induced atrial fibrillation were not different between the heart failure and heart failure-ARB groups. Masson's trichrome staining revealed less fibrosis in the heart failure-ARB group compared with the heart failure group. Immunohistochemical staining and western blot analysis for connexin 43 showed a lower expression level in the heart failure-ARB group compared with that in the heart failure group. In a rat model of ischemic heart failure the ARB losartan had structural and histological atrial reverse-remodeling effects. However, its role as an electrical stabilizer requires further study.

Keywords: angiotensin-II receptor blocker; atrial fibrillation; atrial reverse-remodeling; heart failure

References

  1. Europace. 2004 Sep;5 Suppl 1:S5-19 - PubMed
  2. Ann Surg. 1954 Nov;140(5):675-82 - PubMed
  3. Circulation. 1997 Nov 4;96(9):3157-63 - PubMed
  4. J Am Coll Cardiol. 1992 May;19(6):1136-44 - PubMed
  5. J Am Coll Cardiol. 2000 May;35(6):1669-77 - PubMed
  6. Circ Res. 2005 Jan 7;96(1):54-63 - PubMed
  7. Eur Heart J. 1996 Nov;17(11):1646-56 - PubMed
  8. Europace. 2012 Oct;14(10):1385-413 - PubMed
  9. J Am Coll Cardiol. 2003 Jun 18;41(12):2197-204 - PubMed
  10. Am J Physiol Heart Circ Physiol. 2001 Nov;281(5):H2150-8 - PubMed
  11. J Interv Card Electrophysiol. 2003 Oct;9(2):85-92 - PubMed
  12. Circ J. 2006 May;70(5):575-82 - PubMed
  13. Am J Cardiol. 1997 Aug 4;80(3A):158A-161A - PubMed
  14. Circulation. 1999 Jul 6;100(1):87-95 - PubMed
  15. Circulation. 1994 May;89(5):2273-82 - PubMed
  16. Cardiovasc Res. 2006 Oct 1;72(1):69-79 - PubMed
  17. Circulation. 2003 Jul 22;108(3):360-6 - PubMed
  18. Curr Opin Cardiol. 2006 May;21(3):155-8 - PubMed
  19. Br J Clin Pharmacol. 2008 Sep;66(3):345-51 - PubMed
  20. Europace. 2010 Oct;12(10):1360-420 - PubMed
  21. Circulation. 1994 Jan;89(1):68-75 - PubMed
  22. Circulation. 2000 Jun 6;101(22):2612-7 - PubMed
  23. Circulation. 1998 Feb 24;97(7):686-91 - PubMed
  24. Circulation. 2012 Jan 17;125(2):203-6 - PubMed
  25. Biochim Biophys Acta. 2005 Jun 10;1711(2):154-63 - PubMed
  26. J Am Coll Cardiol. 2003 Jul 16;42(2):336-44 - PubMed
  27. Adv Cardiol. 2006;42:161-174 - PubMed
  28. Eur Heart J. 2012 Aug;33(16):2098-108 - PubMed
  29. Cardiovasc Pathol. 2010 Sep-Oct;19(5):e149-57 - PubMed

Publication Types